skingenix
Clinical Efficacy Studies

Clinical pharmacological studies and extensive clinical experiences indicate that MEBO may maintain wounds in a physiological moist environment, promote microcirculation in wounds, facilitate liquefying and discharging the necrotic tissues, prevent wound from infection, promote wound healing, reduce pains during treatment, improve the quality of healing and minimizes scarring while significantly reducing medical care costs and providing better quality of life. 

 

List of Selected Publication Topics:

  • Pathological Observations
  • Maintaining Physiological Moist Environment, Promoting Healing, and Improving Quality of Healing
  • Improving Microcirculation in Wounds
  •  
    Copyright © 2009-2010 SKINGENIXWEB.COM. All Rights Reserved
    The Skingenix, Inc. website has been designed for the audience worldwide. This website contains information about products which may or may not be available in different countries. In addition, the official approval or market clearance for indications of use may also differ per each country. Please consult individual country sites for approved uses and any applicable restrictions.The research data disclosed in this website is wholly for the purpose of scientific information exchange and is not intended for marketing or promotional uses.

    Please note that Skingenix's drug product MEBO® Wound Ointment has not been approved by the Food and Drug Administration for any indication of use in the United States. It is currently under the status of Investigational New Drug (Phase II) for patients with burn injuries, venous stasis ulcers and diabetic foot ulcers.